Pressure
BioSciences’ (OTCQB: PBIO) pressure cycling technology (“PCT”)
platform was recently the subject of independent research carried out by
Chinese and Australian scientists in which the platform demonstrated its
proficiency in processing of preserved (“FFPE”) and fresh frozen biopsy tissue
samples for the discovery of cancer biomarkers (http://ibn.fm/DfmC7). An article discussing the company
reads, “According to Pressure BioSciences president and CEO Richard T.
Schumacher, over one billion archival tissue samples exist in pathology and
other laboratories across the world. Millions of additional samples are
processed and stored every single year. These samples contain an abundance of
information that could be key to the discovery of new cancer biomarkers,
development of new cancer diagnostics, and release of new treatments and
prevention measures, Schumacher concluded. . . . ‘We believe that our PCT
platform is establishing itself as the method of choice for the superior
extraction of potential biomarkers and their presentation for the effective
proteomic analyses that will propel the growth of this huge market,’ Pressure
BioSciences’ director of marketing and sales Roxana McCloskey added.”
To view the full article, visit http://ibn.fm/NCE8p
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable, high-efficiency,
pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable
nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii)
prepare higher quality, homogenized, extended shelf-life or room temperature
stable low-acid liquid foods that cannot be effectively preserved using
existing non-thermal technologies. For more information, visit the company’s
website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.htm
